Regenics Review: Twelve Peptides FDA Has Named, Sold Behind a Login

Twelve molecules, and one list they all appear on

Here is the catalogue, in full, with the molecules named.

Now the other list.

FDA maintains a page titled "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks", content current as of 22 April 2026. ¹ It sets out the substances FDA reviewed when they were nominated for the 503A bulks list and for which the agency identified a potential significant safety risk, together with what that risk is.

Read down the second column of the table above and check each molecule against it.

BPC-157 is there. Thymosin beta-4 fragment (LKKTETQ), "also known as TB-500", is there. GHK-Cu, "for injectable routes of administration", is there. KPV is there. CJC-1295 is there. Ipamorelin acetate is there twice — once in the withdrawn table and once in category 2 proper, under the 503B interim policy. Emideltide, which is DSIP, is there. Epitalon is there. MOTs-C is there. Selank acetate is there. Semax is there. AOD-9604 is there.

That is twelve for twelve.

The thirteenth molecule is tesamorelin, and its absence is the tell rather than an exception: tesamorelin is not on FDA's page because it is the active ingredient of an approved drug, which is precisely the status the other twelve do not have.

FDA's stated reasons are not identical, and they are worth reading rather than summarising. On MOTS-c: the agency "has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration." On KPV, the same sentence. On BPC-157: it "may pose risk for immunogenicity for certain routes of administration", with "no, or only limited, safety-related information for the proposed routes of administration." On CJC-1295: "FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction."

"The same FDA-inspected standard branded pharmaceuticals are held to"

Against that, here is what a member reads. The sentence is not paraphrased — it appears, near-identically, on every peptide page in the catalogue:

It's compounded for you in a 503 A/B pharmacy, the same FDA-inspected standard branded pharmaceuticals are held to. Most peptides sold online don't go through any of that. Grey-market vendors label vials "for research purposes only" to skirt FDA rules, with no provider and no testing.

Three things are wrong with the first clause and one thing is right about the second, so take them in order.

There is no such thing as a 503 A/B pharmacy. Section 503A of the Food, Drug, and Cosmetic Act describes a state-licensed pharmacy compounding against a prescription for a named patient. Section 503B describes an outsourcing facility that registers with FDA, is subject to FDA inspection and to current good manufacturing practice, and can make batches without patient-specific prescriptions. A company can hold both statuses at different sites, but a vial is made under one regime or the other, and the two carry different inspection regimes, different record-keeping and different limits on what may be compounded at all. Collapsing them into one hyphenated label is not shorthand; it removes the distinction a patient would use to work out who checked the product. If the difference is unfamiliar, 503A and 503B are not two words for the same thing.

No compounded preparation is held to the standard an approved drug is held to. An approved drug has a new drug application, a National Drug Code, an FDA-reviewed label, and a manufacturing process the agency has examined for that specific product. A compounded preparation has none of those, by design, and FDA states so in terms — a compounded drug "is not FDA-approved" and FDA "does not verify the safety or effectiveness of compounded drugs." That distinction survives however clean the pharmacy is, which is why the compounded preparation is not the trial drug.

A 503A pharmacy may not lawfully compound with whatever bulk substance it likes. Under 503A, a bulk drug substance must either comply with a USP or NF monograph, or be a component of an FDA-approved drug, or appear on the 503A bulks list. ² None of the twelve molecules above satisfies any of the three. FDA's interim policy sorts nominated substances into three categories, and the category-1 substances — the ones the agency does not currently intend to act against — are the ones nominated with sufficient information and no identified safety risk. Every molecule in Regenics' peptide catalogue sits instead on the safety-risk page, in a table of nominations that were withdrawn by their nominators before the agency finished.

And the sentence that is right: grey-market vendors really do label vials "for research purposes only" to avoid the rules, with no provider and no testing. That is an accurate description of a real problem, and what "research chemical" actually means is worth understanding. Regenics is on the correct side of it. What the sentence does is use that comparison to make a second claim — that the alternative is a pharmaceutical-grade product held to pharmaceutical standards — and that second claim is where the page stops being accurate.

The one product with an approval, sold outside it

Tesamorelin is the exception in this catalogue, and it is the exception in an instructive way.

It has an FDA approval. The product is EGRIFTA WR, from Theratechnologies, and its label reads: "EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." ³

The evidence behind that is genuinely strong. A 412-patient randomised, double-blind, placebo-controlled phase 3 trial gave 2 mg of tesamorelin or placebo daily for 26 weeks. Visceral adipose tissue, measured by computed tomography, fell 15.2% on drug and rose 5.0% on placebo. ^{4 5} A 263-patient extension study followed. ⁶ Every participant in both had HIV.

Regenics sells the molecule to whoever joins, and pitches it beside weight management: "Pairs with a weight program — patients use it alongside a structured weight or metabolic plan."

The label answers that directly. Under Limitations of Use, immediately after the indication: "EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect." ³

Outside HIV, the registry holds exactly one study of this molecule in abdominal obesity: NCT00675506, Massachusetts General Hospital, "Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity", phase 2, 60 participants, completed January 2012. ⁷ Fourteen years later nothing larger has followed.

So the honest reading is not that Regenics' tesamorelin claim is invented — visceral fat reduction is exactly what this drug does. It is that the population has been quietly swapped, and the swap is the part a buyer cannot see. This is a recurring shape in the growth-hormone secretagogue family, where a real result in a narrow group becomes a general promise.

BPC-157: zero randomised trials, sold as a capsule

The recovery peptide is the volume seller in this category and the one with least behind it.

Regenics' page: "BPC-157 is a peptide that works with the body's tissue-repair process, prescribed for recovery in muscles, tendons, ligaments, and the gut."

As of August 2026, a PubMed search for BPC-157 or "BPC 157" in title or abstract, restricted to the randomised-controlled-trial publication type, returns zero records. ¹⁰ Not a small number. None. Restricting instead to human studies returns 47 records, and reading them, the human work amounts to a handful of small uncontrolled reports — knee pain, interstitial cystitis — plus a pilot study of the safety of intravenous infusion. ¹¹

The registry holds two studies:

NCT02637284 is a phase 1 pilot in healthy volunteers, sponsored by PharmaCotherapia d.o.o., enrolment 42 ESTIMATED, listed completion March 2016. Its status has read UNKNOWN for a decade and no result has been posted. ⁸ That is a common enough fate to have its own pattern, and it means the trial contributes nothing.

NCT07437547 is a phase 2 trial in acute grade II hamstring strain, sponsored by Hudson Biotech, started 2 February 2026, target 120, estimated completion February 2028. ⁹ It is recruiting. It will eventually be evidence. It is not evidence now.

One further detail. Regenics sells BPC-157 as an oral capsule as well as an injection, at $199 retail and $129 to members. Neither registered study tests an oral route. The gap between what people report about healing peptides and what has been trialled is the whole subject, and the capsule sits outside even the anecdote.

Epithalon, and the substance it is not

This is the clearest case on the site, and it turns on two words that differ by three letters.

Regenics sells Epithalon — the synthetic tetrapeptide, four amino acids, alanine-glutamate-aspartate-glycine — to "slow cellular aging" and act on telomerase, at $149 to members.

As of 9 August 2026, a ClinicalTrials.gov v2 intervention search returns zero studies for "Epithalon", zero for "Epitalon" and zero for "Epithalamin". ¹⁴ There is no registered trial of this molecule anywhere in the registry, for any indication.

In PubMed, epitalon, epithalon or AEDG in title or abstract, restricted to randomised controlled trials, returns zero records. Restricted to clinical trials it returns exactly one: a 2002 controlled study of retinal condition in retinitis pigmentosa. ¹⁵

Widen the search and five randomised trials do appear, including one titled "Peptides of pineal gland and thymus prolong human life". ¹⁶ Read them and they test epithalamin — a peptide extract of bovine pineal gland — and all five come from one St Petersburg research group, published between 1999 and 2011, none registered anywhere.

An extract of a gland and a four-amino-acid synthetic peptide are not the same substance, any more than a liver extract is a purified enzyme. The literature that makes epithalon look studied belongs to the other one.

FDA, for its part, names epitalon on its safety-risk page and says the agency "has not identified safety-related information regarding epitalon for the proposed route of administration." ¹

MOTS-c: measuring a peptide is not giving it

The MOTS-c page promises a peptide that "improves how your cells produce energy, which carries into metabolism and exercise capacity."

One trial of the molecule is registered anywhere in the world. NCT07505745, sponsor Hudson Biotech, acronym MOTS-MET: "A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c… in Adults With Prediabetes and Overweight/Obesity." It started on 2 February 2026, targets 120 participants, and estimates completion on 17 May 2028. ¹² It is recruiting.

The randomised human literature that does exist is a different thing entirely, and the difference matters. Four records come back from a PubMed search for MOTS-c restricted to randomised controlled trials. ¹³ In one, the intervention is repeated heat stress. In another, aerobic and resistance exercise. In a third, metformin in breast cancer patients. In the fourth, acute endurance exercise.

In none of the four was anybody given MOTS-c. In all four, circulating MOTS-c is the thing being measured — a marker that rises when people exercise.

That is close to the opposite of the claim on the page. A molecule your body releases more of after exercise is not thereby a molecule that improves your exercise capacity when injected; establishing that would take the trial that opened six months ago. Surrogate markers and outcomes are different objects, and this is the cleanest example of the confusion on the whole site.

The footnote that makes the rest of this worth reading

Now the part of Regenics that deserves genuine credit, because it is rarer than everything above is common.

The compounded-semaglutide page carries a headline — "Patients on semaglutide lose up to 15% of their bodyweight" — sourced to "a 68-week clinical study" of "semaglutide 2.4mg". STEP 1 randomised 1,961 adults with overweight or obesity to once-weekly semaglutide 2.4 mg or placebo for 68 weeks, and reported mean weight change of −14.9% against −2.4%. ^{17 18} The figure is the trial's figure, the duration is the trial's duration, and the strength is named.

Then, at the foot of the same page:

¹Compounded semaglutide is prepared by a licensed compounding pharmacy and is not reviewed or approved by the FDA for safety, effectiveness, or quality. The 15% figure reflects a clinical study of brand-name semaglutide 2.4mg, not the compounded preparation. Results vary and are not guaranteed.

That is the distinction this entire site exists to draw, drawn by the seller, attached to the exact number it qualifies. Most competitors quote the trial figure beside a compounded vial and let the reader assume they are the same object.

The Zepbound page is similarly careful. It quotes SURMOUNT-1's 72-week range as "16% to 22.5% of their body weight, depending on dose", which is the more flattering of the two published estimands — the other reports −15.0%, −19.5% and −20.9% ^{19 20} — but correctly ties the top of the range to the highest dose. It then reports the 176-week diabetes-prevention result, where 1.3% of participants with prediabetes on tirzepatide and 13.3% on placebo were diagnosed with type 2 diabetes, hazard ratio 0.07. ²¹ Regenics rounds that to a 94% relative risk reduction where the published hazard ratio gives 93%, and then adds, without being asked: "Absolute risk reduction and individual outcomes vary based on baseline risk and adherence."

A relative-risk headline with an absolute-risk caveat volunteered underneath it is not something this category does.

The screening comes after the sale

One structural detail, from the same public endpoint, reported precisely because it is checkable.

Every product row carries a boolean, `requiresClearance`. It is true for the GLP-1 protocols, testosterone replacement, NAD+, glutathione, CoQ10, PT-141, the B12 and biotin kits, metformin, the lipotropic injections, ondansetron, omeprazole and the ED drugs.

It is false for all fourteen peptide SKUs, and for both AOD-9604 presentations.

What that flag controls is not documented publicly, so this review does not assert that it means no clinician reviews a peptide order. What is documented, in the application's own code, is the set of forms the flag triggers, and every identifier in that set is named the same way: `weight_loss_postpurchase_form`, `pt141_postpurchase_form`, `nad_postpurchase_form`, `glutathione_postpurchase_form`, and nine more. The word in each of them is postpurchase.

So on the products that do carry a clearance requirement, the health screening is something a customer completes after paying. On the peptides — the fourteen products whose molecules FDA has publicly flagged — the flag is off.

What it adds up to

Set the two halves beside each other.

On one side: a Tarzana clinic with a street address and office hours, a named medical corporation in the patient agreement, in-office lab draws, the approved GLP-1 drugs offered alongside the compounded ones, membership tiers published in full, trial numbers that match the trials, and a footnote about compounded semaglutide that most of this industry would refuse to write.

On the other: thirteen molecules sold from behind a paywall, twelve of them named on FDA's own page of bulk substances that may present significant safety risks, each described to the buyer as compounded to "the same FDA-inspected standard branded pharmaceuticals are held to" — a standard that does not apply, in a pharmacy category that does not exist, with no certificate of analysis for any lot and no pharmacy named on any page a customer can read.

The company that wrote the semaglutide footnote knows exactly what distinction it is declining to draw everywhere else. That is not an accident of copywriting. It is a claim outrunning its evidence, on the one part of the catalogue where nobody can check it before paying.